Zeposia gives 6 years without relapse in trial

In the recent findings presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, it was revealed that Zeposia (ozanimod) demonstrated remarkable effectiveness in treating relapsing forms of multiple sclerosis (MS). Results from the DAYBREAK clinical trial showcased a significant milestone, with approximately two-thirds of participants experiencing complete freedom from relapses over a six-year treatment period.

Furthermore, a substantial portion of individuals did not encounter sustained disability progression during this time frame, and the incidence of new or enlarging lesions remained consistently low compared to those treated with Avonex (interferon beta-1a), an established therapy for MS. These outcomes were unveiled in the final analysis of the DAYBREAK open-label extension study.

Funded by Bristol Myers Squibb, the pharmaceutical company behind Zeposia, the study’s findings were highlighted by Jonathan Sadeh, MD, Senior Vice President at Squibb, who emphasized the consistent and sustained safety and efficacy profile of Zeposia. He remarked that these results further solidify Zeposia’s pivotal role in the treatment landscape for MS.

Zeposia, an oral medication designed to mitigate inflammation in the brain and spinal cord, is currently only available on the NHS in Scotland for relapsing forms of MS.